Ash 2022 preview – Affimed and Aptose score
In oncology settings outside multiple myeloma investors have picked two early winners.
Johnson & Johnson waits until the last to drop Geron
A new partnership hunt awaits Geron Corporation as it seeks to defray the costs of the phase III imetelstat programme, making Ash presentations a key moment in the…
